Spasticity Market: Rapid Growth & Investment Outlook to 2032 - DelveInsight

The Spasticity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spasticity pipeline products will significantly revolutionize the Spasticity market dynamics.

DelveInsight's "Spasticity Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spasticity market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Spasticity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spasticity Market Insights
https://www.delveinsight.com/sample-request/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Spasticity Market Report:
• The Spasticity market size was valued approximately USD 904 million in 2021 is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In July 2025, A global Phase 2 clinical trial, BALANCE-MSS-1 (NCT06782490), has been initiated to assess the oral therapy candidate BMS-986368 for the treatment of spasticity - characterized by muscle stiffness and spasms - in individuals with multiple sclerosis (MS). The study aims to enroll around 200 adult MS patients who have been experiencing spasticity for at least six months. Trial sites are located in the U.S., Australia, Canada, Puerto Rico, and several European countries, with some already open for recruitment. The trial is sponsored by Celgene and conducted by Bristol Myers Squibb, which acquired Celgene in 2019.
• In April 2025, The US FDA has approved BlackfinBio's IND application to initiate a Phase I/II trial of BFB-101, an adeno-associated virus gene therapy for hereditary spastic paraplegia type 47 (SPG47). The therapy has also received orphan drug and rare pediatric disease designations for SPG47, a rare disorder caused by AP4B1 gene mutations, leading to progressive lower-limb spasticity and developmental delays in children.
• In January 2024, Ipsen (Euronext: IPN; ADR: IPSEY) recently revealed top-line results from its real-world AboLiSh study (NCT04050527), presented at the 7th International TOXINS Conference in Berlin, Germany. The study assessed the use and effectiveness of Dysport® (abobotulinumtoxinA) in individuals with lower-limb spasticity, highlighting that injection guidance techniques notably enhance patient outcomes and goal achievement.
• Spasticity is one of the most common symptoms of multiple sclerosis (MS) and is defined as muscle stiffness that is frequently generalized and that causes more or less continuous rigidity
• There were approximately 2,328,000 prevalent cases of Spasticity in the United States in 2021
• According to the analysis, DelveInsight estimated approximately 415,000 prevalent cases of Spasticity in Germany in 2021
• Key Spasticity Companies: Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others
• Key Spasticity Therapies: Nabiximols, DAXI, IPN10200, and others
• The Spasticity epidemiology based on gender analyzed that Males are more at risk of developing Spasticity in comparison to the females

Spasticity Overview
Spasticity is defined as "sensorimotor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex" or from an upper motor neuron lesion (UMN),presenting as an intermittent or sustained involuntary activations of muscles. The region and the extent of impairment depend on the area of the brain or spinal cord that has been damaged. It can occur in the upper and/or lower limbs

Get a Free sample for the Spasticity Market Report:
https://www.delveinsight.com/report-store/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spasticity Market
The dynamics of the Spasticity market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032.
"The emerging therapies for the treatment of Spasticity include Nabiximols, DAXI and others. Approval of these therapies will provide new and different treatment options to the patients and will hence drive the market."

Spasticity Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Spasticity Epidemiology Segmentation:
The Spasticity market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Spasticity
• Prevalent Cases of Spasticity by severity
• Gender-specific Prevalence of Spasticity
• Diagnosed Cases of Episodic and Chronic Spasticity

Download the report to understand which factors are driving Spasticity epidemiology trends @ Spasticity Epidemiological Insights
https://www.delveinsight.com/sample-request/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spasticity Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spasticity market or expected to get launched during the study period. The analysis covers Spasticity market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Spasticity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Spasticity Therapies and Key Companies
• Nabiximols: Jazz Pharmaceuticals
• DAXI: Revance Therapeutics
• IPN10200: Ipsen

To know more about Spasticity treatment, visit @ Spasticity Medications
https://www.delveinsight.com/sample-request/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Spasticity Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Spasticity Companies: Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others
• Key Spasticity Therapies: Nabiximols, DAXI, IPN10200, and others
• Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies
• Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Spasticity Unmet Needs, KOL's views, Analyst's views, Spasticity Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.